Abstract 1501P
Background
The Gender differences in the clinical symptoms presentation (CSP) are known and already studied in many settings of medicine, such as Cardiology and Neurology. However, these differences have been studied less deeply in Oncology and Palliative Care. Our analysis focused on evluating how gender can affect the CSP in an integrated outpatient clinic between Radiotherapy and Palliative Care (RaP).
Methods
This is a monocentric, observational study carried out in the RaP integrated outpatient clinic in a Research Cancer Hospital (IRCCS, IRST - Meldola, Italy). Descriptive statistics were reported for each Edmonton Symptom Assessment System (ESAS) item, separately by gender. Additionally, a set of linear models were developed to predict ESAS items score. Multivariable linear model incorporated all other symptoms, clinical characteristics (e.g tumor location), and the sex variable to evaluate possible gender effects. All analyses were performed using R statistical software.
Results
212 patients were enrolled in the study between 2016 and 2020. Most of the symptoms showed significant gender differences. Specifically, the symptom "Pain” showed higer values in the male population (mean: M5.1 vs. F 4.4). Conversely, the symptom "Anxiety” showed higer values in the female population (mean. M 2.0 vs F 3.0). Finally, the "total symptom distress score” resulted in higer values in the female population (mean: M 23.0 vs F 25.4). Interestingly, the symptom "malaise” is the only that showed an almost perfect equity for all values (mean M1.9 vs F 2.0). The linear model aimed at assessing, ceteris paribus, report 0.9 additional points than females (p= 0.053). Conversely, keeping constant all other factors, females report 0.95 higer expression of anxiety (p=0.002).
Conclusions
The gender differences in the CSP and their distribution highligheted in our analysis are important in the new subfield of medicine called "Gender Medicine". Especially in palliative care, data relating to patients symptoms is necessary to reach the goal of the best supoportive care. Additional studeis will be necessary to improve our knowledge in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Tontini.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract